9IPW

Crystal structure of VHL-EloB-EloC in complex with a fragment compound 7HC_5(D3)

これはPDB形式変換不可エントリーです。

9IPW の概要

• エントリーDOI: 10.2210/pdb9ipw/pdb
• 分子名称: Elongin-B, Elongin-C, von Hippel-Lindau disease tumor suppressor, ... (5 entities in total)
• 機能のキーワード: e3 ligase, elob, eloc, protein binding
• 由来する生物種: Homo sapiens (human); 詳細
• タンパク質・核酸の鎖数: 12
• 化学式量合計: 167155.24

構造登録者

Lee, B.I.,Kim, Y. (登録日: 2024-07-11, 公開日: 2025-01-29, 最終更新日: 2025-07-02)

主引用文献

Kim, Y.,Baek, S.J.,Yoon, E.K.,Choi, M.,Kim, J.H.,Kim, K.,Park, C.H.,Lee, B.I.
Identification of novel 7-hydroxycoumarin derivatives as ELOC binders with potential to modulate CRL2 complex formation.
Sci Rep, 15:3622-3622, 2025

PubMed Abstract: The VHL-containing cullin-RING E3 ubiquitin ligase (CRL2) complex is an E3 ligase commonly used in targeted protein degradation (TPD). Hydroxyproline-based ligands that mimic VHL substrates have been developed as anchor molecules for proteolysis-targeting chimeras (PROTACs) in TPD. To expand the chemical space for VHL ligands, we conducted fragment screening using VHL-ELOB-ELOC (VBC) proteins. We found that certain 7-hydroxycoumarin derivatives (7HCs), rather than VHL, would bind to the ELOC component of the VBC complex. The 7HC binding site overlapped with the CUL2 binding interface on ELOC but did not overlap with the CUL5 binding interface, suggesting that 7HCs may influence the formation of CRL2 but not CRL5. Although the binding affinities of these 7HCs to the VBC complex were relatively low, they represent novel and promising foundational agents for the development of chemical probes or inhibitors that target ELOC-containing CRLs.

PubMed: 39881207
DOI: 10.1038/s41598-025-88166-2

実験手法

X-RAY DIFFRACTION (3 Å)